Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is the most common neurodegenerative disease, with
characteristic extracellular amyloid-β (Aβ) deposition and intracellular accumulation of …

Microglia are the resident macrophages of the central nervous system (CNS) acting as the
first line of defense in the brain by phagocytosing harmful pathogens and cellular debris …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Abnormal assembly of tau, α-synuclein, TDP-43 and amyloid-β proteins into amyloid
filaments defines most human neurodegenerative diseases. Genetics provides a direct link …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …